Compass Therapeutics Future Growth
Future criteria checks 2/6
Compass Therapeutics is forecast to grow earnings and revenue by 50.7% and 66.1% per annum respectively while EPS is expected to grow by 52.5% per annum.
Key information
50.7%
Earnings growth rate
52.5%
EPS growth rate
Biotechs earnings growth | 24.6% |
Revenue growth rate | 66.1% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 03 Jun 2024 |
Recent future growth updates
Recent updates
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Jun 05We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Feb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth
Sep 20Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial
Oct 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 69 | -45 | N/A | -59 | 7 |
12/31/2025 | 5 | -71 | N/A | -55 | 7 |
12/31/2024 | N/A | -55 | N/A | -48 | 7 |
3/31/2024 | N/A | -45 | -42 | -42 | N/A |
12/31/2023 | N/A | -42 | -41 | -41 | N/A |
9/30/2023 | N/A | -41 | -39 | -39 | N/A |
6/30/2023 | N/A | -43 | -44 | -44 | N/A |
3/31/2023 | N/A | -40 | -38 | -38 | N/A |
12/31/2022 | N/A | -39 | -34 | -34 | N/A |
9/30/2022 | N/A | -41 | -29 | -28 | N/A |
6/30/2022 | N/A | -35 | -22 | -21 | N/A |
3/31/2022 | N/A | -82 | -24 | -22 | N/A |
12/31/2021 | N/A | -82 | -22 | -20 | N/A |
9/30/2021 | N/A | -78 | -23 | -22 | N/A |
6/30/2021 | N/A | -81 | -26 | -25 | N/A |
3/31/2021 | N/A | -31 | -25 | -25 | N/A |
12/31/2020 | N/A | -29 | -27 | -27 | N/A |
9/30/2020 | N/A | -28 | -26 | -26 | N/A |
6/30/2020 | N/A | -27 | -26 | -25 | N/A |
3/31/2020 | N/A | -30 | -29 | -29 | N/A |
12/31/2019 | N/A | -35 | -32 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CMPX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CMPX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CMPX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CMPX's revenue (66.1% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: CMPX's revenue (66.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CMPX's Return on Equity is forecast to be high in 3 years time